山东三元生物科技股份有限公司 2023年度独立董事述职报告 （朱宁） 尊敬的各位股东及股东代表： 本人作为山东三元生物科技股份有限公司（以下简称"公司"）第四届董 事会的独立董事，任职期间严格按照《公司法》《证券法》《上市公司独立董 事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2 号——创业板上市公司规范运作》等相关法律法规以及 《公司章程》《独立董事工作制度》的规定和要求，认真履行独立董事职责， 出席相关会议，对各项议案进行认真审议，充分发挥独立董事的独立性和专业 性作用，积极促进公司规范运作，切实维护公司全体股东尤其是中小股东的合 法利益。 因个人原因，本人于2023年10月23日向公司董事会申请辞去第四届独立董 事、董事会薪酬与考核委员会主任委员及董事会审计委员会委员职务，辞职后 不再担任公司任何职务。公司于2023年10月26日、11月13日召开了第四届董事 会第十八次会议及2023年第三次临时股东大会，会议审议通过了《关于补选公 司第四届董事会独立董事的议案》。本人自2023年11月13日起，不再担任公司 第四届董事会独立董事及第四届董事会薪酬与考核委员会 ...

根据公司业务发展及日常经营需要，公司预计 2024 年度与关联方滨州三元 家纺有限公司发生日常性关联交易，预计金额不超过 4,000,000.00 元（不含税）。 公司 2023 年度实际发生的日常关联交易总金额为 1,694,676.11 元。 （二）2024 年度预计日常性关联交易类别和金额 单位：元 | 关联交易类别 | 关联人 | 关联交易内容 | 关联交易 | 预计金额 | 截至披露日 | 上年度发生 | | --- | --- | --- | --- | --- | --- | --- | | | | | 定价原则 | | 已发生金额 | 金额 | | 接受关联方劳务服 务（污水处理） | 滨州三元家 纺有限公司 | 委托关联方代 为进行污水处 | 市场定价 | 4,000,000.00 | 666,966.38 | 1,694,676.11 | | | | 理 | | | | | | 合计 | | | | 4,000,000.00 | 666,966.38 | 1,694,676.11 | 中信建投证券股份有限公司 关于山东三元生物科技股份有限公司 2024 年度日常关联交易预计情况的核查意见 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 191,894,599.16, representing a 65.03% increase compared to CNY 116,276,458.04 in the same period last year[4] - Net profit attributable to shareholders reached CNY 24,247,672.28, a significant increase of 210.54% from CNY 7,808,194.59 year-on-year[4] - Basic and diluted earnings per share both increased to CNY 0.12, marking a 200.00% rise from CNY 0.04 in the same quarter last year[4] - Operating profit reached CNY 25,374,529.81, up from CNY 12,876,263.21, reflecting a growth of 96.5% year-over-year[23] - The company's net profit attributable to shareholders increased to ¥769,310,662.69 from ¥745,062,990.41, showing a growth of about 3.2%[21] Cash Flow and Liquidity - The net cash flow from operating activities surged by 744.81% to CNY 22,158,704.92, up from CNY 2,622,930.65 in the previous year[9] - Cash flow from operating activities generated a net amount of CNY 22,158,704.92, compared to CNY 2,622,930.65 in Q1 2023, marking an increase of 743.5%[25] - Total cash and cash equivalents at the end of the period were CNY 95,348,055.91, down from CNY 142,378,891.60, a decrease of 32.9%[26] - The cash and cash equivalents decreased to ¥101,631,627.34 from ¥108,808,330.03, a decline of about 6.5%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,882,280,669.13, reflecting a 1.49% increase from CNY 4,810,426,435.78 at the end of the previous year[4] - The total assets of the company as of the end of Q1 2024 were ¥4,882,280,669.13, compared to ¥4,810,426,435.78 at the beginning of the period, marking an increase of approximately 1.5%[21] - The company's total liabilities increased to ¥320,010,491.34 from ¥272,403,930.27, representing a growth of approximately 17.5%[21] Operating Costs and Expenses - The company reported a 44.95% increase in operating costs, attributed to higher sales volume and increased sales prices[8] - Total operating costs for Q1 2024 were ¥194,873,387.02, up from ¥135,685,668.54, indicating an increase of about 43.5%[22] - Research and development expenses rose by 34.31% compared to the previous year, indicating the company's commitment to enhancing competitiveness through increased investment in R&D[8] - Research and development expenses amounted to ¥15,833,077.03, compared to ¥11,788,523.18 in the prior period, reflecting a rise of approximately 34.3%[22] Shareholder Information - The total number of restricted shares held by major shareholders at the end of the period is 98,780,906 shares, with 127,969 shares released during the period[14] - The company reported a total of 5,110,900 shares held by Shanghai Tongyi Investment Management Co., Ltd., through various accounts[12] - The top 10 shareholders include significant holdings by Wang Shen and Wang Meihua, who are acting in concert[12] - The company has a total of 1,992,629 shares held by Beijing Yian Capital Management Co., Ltd., accounting for 0.98% of total share capital[13] - The company’s major shareholders include several private equity funds managed by Shenzhen Nanfang Xintai, with significant holdings reported[12] - The company has a total of 3,715,445 shares held by Shenzhen Nanfang Xintai Private Equity Fund, indicating strong institutional support[12] Financial Management Strategy - The company plans to use up to RMB 240 million of temporarily idle raised funds for cash management within 12 months, approved by the board and shareholders[15] - The company also intends to use up to RMB 100 million of temporarily idle self-owned funds for cash management, with a similar 12-month usage period[16] - The company’s financial management strategy includes rolling use of funds within the approved limits and timeframes[15] - The company’s management is authorized to make investment decisions within the specified limits for cash management[16] Other Financial Metrics - The weighted average return on net assets improved to 0.53%, up from 0.17% in the same period last year[4] - Other income decreased by 34.35% year-on-year, primarily due to a reduction in penalty income during the reporting period[8] - The company did not report any net profit from subsidiaries under common control during the period[24] - The report was not audited, which may affect the reliability of the financial data presented[27]

山东三元生物科技股份有限公司 董事会议事规则 二〇二四年四月 | 第一章 | 总 则 | 2 | | --- | --- | --- | | 第二章 | 董事会的组成和职权 | 2 | | 第三章 | 董事及董事长的权利、义务与责任 | 4 | | 第四章 | 董事会会议的召开 | 8 | | 第五章 | 董事会会议的议事程序与决议 | 10 | | 第六章 | 董事会决议的执行 | 13 | | 第七章 | 附 则 | 13 | 山东三元生物科技股份有限公司 董事会议事规则 第一章 总 则 第一条 为完善山东三元生物科技股份有限公司（以下简称"公司"）法人治 理结构，规范董事会及其成员的组织和行为，保证董事会议事程序及其决议的合 法性，确保董事会高效运作和科学决策，维护公司、股东、债权人及公司职工的 合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司治理准则》、《上市公司章程指引》、《深圳证券交易所创业板股票上市 规则》、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等法律、法规、规范性文件的有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 董 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-031 山东三元生物科技股份有限公司 关于修订《公司章程》及制定、修改公司治理相关制 度的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召开了第四届董事会第二十次会议、第四届监事会第十六次会议，审议通过了 《关于修订<公司章程>的议案》及《关于制定、修改公司治理相关制度的议案》。 现将具体情况公告如下： 一、《公司章程》修订情况 根据《公司法》《证券法》《上市公司章程指引》《上市公司独立董事管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件的最新规定， 结合公司实际情况，拟对《山东三元生物科技股份有限公司章程》（以下简称"公 司章程"）中的部分条款进行修订。具体修订内容如下： | 序号 | 修订前 | 修订后 | | --- | --- | --- | | 1 | 第四十八条 独立董事有权向董事 | 第四十八条 独立 ...

山东三元生物科技股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 证券代码：301206 证券简称：三元生物 公告编号：2024-023 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召开了第四届董事会第二十次会议、第四届监事会第十六次会议，会议审议通 过了《关于 2023 年度利润分配预案的议案》。现将具体情况公告如下： 一、利润分配预案的基本情况 经大华会计师事务所（特殊普通合伙）审计，公司 2023 年度合并报表中归 属于上市公司股东的净利润为 58,874,449.10 元，母公司报表的净利润为 59,374,403.35 元，提取法定盈余公积金后，公司合并报表累计未分配利润为 745,062,990.41 元，母公司报表累计未分配利润为 746,888,745.83 元。根据《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等规 定，按照合并报表、母公司报表中可供分配利润孰低的原则，2023 年度公司可 供股东分配利润为 745,062,9 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-029 山东三元生物科技股份有限公司 2023 年年度股东大会通知公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）第四届董事会第二十 次会议决定于 2024 年 5 月 15 日（星期三）召开公司 2023 年年度股东大会，现 将本次会议有关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2023 年年度股东大会 （二）股东大会的召集人：公司董事会。 （三）会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 （四）会议召开的日期、时间： 1、现场会议召开时间：2024 年 5 月 15 日（星期三）15:00 2、网络投票时间：2024 年 5 月 15 日（星期三） （1）通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 5 月 15 日 9:15-9:25，9:30-11:30，13:00-15:00。 （1）现场投票：股东本人出席现场会议或者通过授权委托书 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-033 山东三元生物科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）根据中华人民共和国 财政部（以下简称"财政部"）颁布的《企业会计准则解释第 17 号》（财会【2023】 21 号，以下简称"《准则解释第 17 号》"）的要求变更会计政策，本次会计政 策变更无需提交公司董事会和股东大会审议，不会对公司财务状况、经营成果和 现金流量产生重大影响。现将具体情况公告如下： 一、本次会计政策变更概述 （一）会计政策变更原因及变更日期 2023 年 10 月 25 日，财政部发布了《准则解释第 17 号》，解释了"关于流 动负债与非流动负债的划分"、"关于供应商融资安排的披露"和"关于售后租回 交易的会计处理"内容，自 2024 年 1 月 1 日起施行。 公司根据上述会计准则解释规定，对会计政策进行相应变更。其中"关于售 后租回交易的会计处理"内容允许企业自发布年度提前执行，公司自 2023 年 10 月 25 日起 ...

Financial Performance - The company faced unprecedented challenges in the erythritol industry, leading to overcapacity and intensified competition, resulting in a decline in sales revenue and profits [4]. - The company's sales revenue and profits both experienced a year-on-year decline due to the dual impact of price and volume [4]. - The company's operating revenue for 2023 was ¥499,500,775.41, a decrease of 25.99% compared to ¥674,905,595.63 in 2022 [24]. - The net profit attributable to shareholders for 2023 was ¥58,874,449.10, down 64.03% from ¥163,686,641.34 in the previous year [24]. - The basic earnings per share for 2023 was ¥0.29, a decline of 64.63% from ¥0.82 in 2022 [24]. - The gross profit margin for erythritol was 10.50%, down from 11.61% in the previous year, while the gross profit margin for blended sweeteners was 28.24%, a decrease of 14.12% [70]. - The company reported a total operating cost of CNY 484,265,065, which represents a decrease of 16.51% from CNY 580,046,467 in 2022 [71]. - The company's revenue for 2023 was 499.50 million yuan, a decrease of 25.99% compared to the previous year, while net profit fell by 64.03% to 58.87 million yuan [156]. Cash Flow and Assets - The cash flow from operating activities for 2023 was ¥57,310,770.18, a decrease of 31.99% compared to ¥84,264,654.04 in 2022 [24]. - The total assets at the end of 2023 were ¥4,810,426,435.78, a slight decrease of 1.22% from ¥4,869,919,341.29 at the end of 2022 [24]. - The net assets attributable to shareholders at the end of 2023 were ¥4,538,022,505.51, down 1.79% from ¥4,620,776,046.41 in 2022 [24]. - The company's total assets included cash and cash equivalents of ¥108,808,330.03, down from ¥489,042,093.26 at the beginning of the year, a decrease of 7.78% [123]. Market and Industry Trends - The functional sugar market, particularly erythritol, has seen rapid growth, with China's production reaching 139,000 tons in 2022, accounting for 78.9% of global output [36]. - The price of erythritol dropped to CNY 9,500 per ton in H1 2023 due to excess capacity, but has since stabilized at CNY 10,200 per ton as of November 20, 2023 [41]. - The market for functional sugars is expected to stabilize as excess capacity is gradually eliminated, benefiting companies with high efficiency and quality products [42]. - The functional sugar industry in China is experiencing robust growth, supported by government policies and regulations aimed at promoting health and reducing sugar consumption [45]. - The market size for the sugar-free beverage industry in China is projected to reach approximately 748.9 billion CNY by 2027, with a compound annual growth rate (CAGR) of 10.80% from 2023 to 2027 [48]. Product Development and Innovation - The company is focusing on the development of functional foods and health products, which are expected to drive future growth [24]. - The company is actively pursuing new product development and technological innovation to maintain its competitive edge in the market [81]. - The company aims to enhance its product variety by developing new products such as steviol glycosides and sodium hyaluronate, which have successfully completed pilot testing [146]. - The company has developed over 20 varieties of blended sugars, including monk fruit and stevia blends, tailored to market demands [59]. - The company is currently developing a fermentation process for producing rare sugars, which is expected to diversify product offerings and create new business growth points [116]. Competitive Strategy - The company plans to maintain a pricing strategy slightly above industry peers to protect shareholder interests amid intense competition [41]. - The company emphasizes a differentiated competitive strategy focused on market demand and continuous innovation in functional sugars [57]. - The company has maintained a cost advantage in erythritol production, leveraging over ten years of experience in cost control [78]. - The company is committed to enhancing product quality and expanding market share through innovative packaging and product strategies [66]. Governance and Management - The company has established a board of directors consisting of 9 members, including 3 independent directors, complying with relevant laws and regulations [165]. - The company has a supervisory board with 3 members, including 1 employee supervisor, ensuring compliance with legal requirements [166]. - The company maintains independence from its controlling shareholders, with no unauthorized use of company funds or interference in decision-making [167]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status [168]. Research and Development - The company has increased its R&D efforts, focusing on new product development in the functional sugar sector, including high-quality stevia and sodium hyaluronate [99]. - The company's R&D investment amounted to ¥50,661,533.15 in 2023, representing 10.14% of operating revenue, a significant increase from 5.05% in 2022 [117]. - The company has achieved a target of ≥98% purity for the refined Reb M product, enhancing its market competitiveness [116]. - The company has developed core patents related to the fermentation extraction of erythritol, enhancing its production efficiency and competitiveness [91]. Customer and Supplier Relations - The company's top five distributors accounted for 27.75% of total sales revenue, with sales amounting to CNY 138,598,672.17 [74]. - The company has established long-term stable partnerships with local raw material suppliers, reducing procurement costs and transportation risks [88]. - The top five customers accounted for 36.12% of total sales, indicating a high customer concentration risk [158]. Future Outlook - The company has set a future outlook with a revenue target of 1.8 billion RMB for 2024, indicating a projected growth of 20% [190]. - The company plans to enhance market competitiveness by expanding its R&D efforts and product offerings [117]. - The company plans to increase its R&D budget by 25% in 2024, focusing on sustainable and eco-friendly product lines [190]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish two new distribution centers by mid-2024 [190].

（一）审议通过《2023 年度监事会工作报告》； 证券代码：301206 证券简称：三元生物 公告编号：2024-028 山东三元生物科技股份有限公司 第四届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 山东三元生物科技股份有限公司（以下简称"公司"）第四届监事会第十六 次会议于 2024 年 4 月 22 日下午 2:30 在公司会议室以现场方式召开。会议通知 于 4 月 11 日以书面、电话方式通知到各位监事，本次会议应到监事 3 人，实到 监事 3 人，会议由监事会主席崔振乾主持，会议的召集、召开和表决程序符合《公 司法》和《公司章程》的有关规定，所作决议合法有效。 二、议案审议情况 本次会议以记名投票表决方式表决通过如下议案： 公司监事会主席崔振乾先生代表监事会作 2023 年度监事会工作报告。 具体内容详见公司于 2024 年 4 月 23 日在巨潮资讯网（www.cninfo.com.cn） 披露的《2023 年度监事会工作报告》。 表决结果：3 票同意，0 票反对，0 票弃权。 回避表决情况：本 ...